Livmoniplimab Clinical Trials (2026): 6 Studies for Hepatocellular Carcinoma & Advanced Solid Tumors Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
6 Livmoniplimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Hepatocellular Carcinoma & Advanced Solid Tumors Cancer) and 1,576 total planned enrollment. 1 Livmoniplimab clinical trial is actively recruiting at 12 U.S. sites across 10 states. Most recent activity: NCT06236438 (Oct 2031).
Where to Participate: All Livmoniplimab Trial Sites in the U.S. (12 sites across 10 states)
Every actively recruiting Livmoniplimabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Bond Clinic /ID# 262611 | Winter Haven33880 | NCT06236438 | Map |
| GA | University Cancer and Blood Cent /ID# 261824 | Athens30607 | NCT06236438 | Map |
| IL | The University of Chicago Medical Center /ID# 262259 | Chicago60637-1443 | NCT06236438 | Map |
| KS | University of Kansas Medical Center /ID# 263196 | Westwood66205 | NCT06236438 | Map |
| KY | Baptist Health Lexington /ID# 261823 | Lexington40503 | NCT06236438 | Map |
| MI | Cancer & Hematology Centers of Western Michigan - East /ID# 261826 | Grand Rapids49546-7062 | NCT06236438 | Map |
| MO | Washington University-School of Medicine /ID# 262759 | St Louis63110 | NCT06236438 | Map |
| OH | Oncology Hematology Care, Inc - Blue Ash /ID# 262733 | Cincinnati45252 | NCT06236438 | Map |
| TX | Houston Methodist Hospital /ID# 262722 | Houston77030 | NCT06236438 | Map |
| TX | Texas Oncology - Plano East /ID# 264356 | Plano75075 | NCT06236438 | Map |
| TX | Texas Oncology - San Antonio Medical Center - Research Drive /ID# 264311 | San Antonio78240 | NCT06236438 | Map |
| WA | Vista Oncology - East Olympia /ID# 262303 | Olympia98506-5028 | NCT06236438 | Map |
Livmoniplimab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1 | 2 | 2 | |
| P2 | 2 | 2 | |
| P2/P3 | 1 | 1 | 2 |
Recruiting Livmoniplimab clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06236438 | LIVIGNO-4Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | P2/P3 | Non-Small Cell Lung Cancer | 840 | Apr 2024 |
Livmoniplimab clinical trials by indication
Hepatocellular Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06109272 | LIVIGNO-2 | P2/P3 | active not recruiting | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) |
| NCT05822752 | LIVIGNO-1 | P2 | active not recruiting | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) |
Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06632951 | LIVIGNO-3 | P2 | active not recruiting | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) |
Hepatocellular Carcinoma (HCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06487559 | HCC | P1 | active not recruiting | A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) |
Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06236438 | LIVIGNO-4 | P2/P3 | recruiting | Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Advanced Solid Tumors Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03821935 | RP2D | P1 | active not recruiting | Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors |
Livmoniplimab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| LIVIGNO-3 | NCT06632951 | P2 | active not recruiting | Urothelial Carcinoma | 150 | — |
| LIVIGNO-1 | NCT05822752 | P2 | active not recruiting | Hepatocellular Carcinoma | 130 | — |
All Livmoniplimab trials (6)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06236438 | LIVIGNO-4 | Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | P2/P3 | recruiting | 840 | AbbVie | Apr 2024 |
| NCT06632951 | LIVIGNO-3 | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) | P2 | active not recruiting | 150 | AbbVie | Jan 2025 |
| NCT03821935 | RP2D | Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | P1 | active not recruiting | 364 | AbbVie | Feb 2019 |
| NCT06487559 | HCC | A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) | P1 | active not recruiting | 3 | AbbVie | Sep 2024 |
| NCT06109272 | LIVIGNO-2 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | P2/P3 | active not recruiting | 89 | AbbVie | Jan 2024 |
| NCT05822752 | LIVIGNO-1 | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | P2 | active not recruiting | 130 | AbbVie | Sep 2023 |
Livmoniplimab clinical trials: frequently asked questions
- How many Livmoniplimab clinical trials are there?
- 6 Livmoniplimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are Livmoniplimab clinical trials recruiting in 2026?
- Yes — 1 Livmoniplimab trial is actively recruiting in 2026, with 12 U.S. sites across 10 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Livmoniplimab being studied for?
- Livmoniplimab is being studied for Hepatocellular Carcinoma, Advanced Solid Tumors Cancer, Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer, Urothelial Carcinoma. The trials are grouped by indication on this page.
- What phase is Livmoniplimab in?
- Livmoniplimab clinical trials span 2 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Livmoniplimab clinical trials?
- The lead sponsor across the most Livmoniplimab trials is AbbVie. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Livmoniplimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: